Structure-guided modification of a lead cholinesterase-targeting oxime to improve peripheral site binding
References
- Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2(6150):1457–9. doi: 10.1136/bmj.2.6150.1457
- Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Muñoz-Torrero D, Luque FJ. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2010;16:2818–36. doi: 10.2174/138161210793176536
- Inoue A, Kawai T, Wakita M, Imura Y, Sugimoto H, Kawakami Y. The simulated binding of (+/−)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]meth yl] -1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses. J Med Chem 1996;39:4460–70. doi: 10.1021/jm950596e
- Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res 2005;1060:144–52. doi: 10.1016/j.brainres.2005.08.039
- Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88–93. doi: 10.1006/nbdi.2001.0462
- Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem Res 2003;28:515–22. doi: 10.1023/A:1022869222652
- Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993;58:51–66. doi: 10.1016/0163-7258(93)90066-M
- Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003;22:165–90. doi: 10.2165/00139709-200322030-00004
- Jokanović M, Stojiljković MP. Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning. Eur J Pharmacol 2006;553:10–7. doi: 10.1016/j.ejphar.2006.09.054
- Radić Z, Sit RK, Kovarik Z, Berend S, Garcia E, Zhang L, Amitai G, Green C, Radić B, Fokin VV, Sharpless KB, Taylor P. Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem 2012;287:11798–809. doi: 10.1074/jbc.M111.333732
- Knežević A, Vinković V, Maraković N, Šinko G. Enzyme-catalyzed cascade synthesis of hydroxyiminoacetamides. Tetrahedron Lett 2014;55:4338–41. doi: 10.1016/j.tetlet.2014.06.027
- Maraković N, Knežević A, Vinković V, Kovarik Z, Šinko G. Design and synthesis of N-substituted-2-hydroxyiminoacetamides and interactions with cholinesterases. Chem Biol Interact 2016;259:122–32. doi: 10.1016/j.cbi.2016.05.035
- Maraković N, Knežević A, Rončević I, Brazzolotto X, Kovarik Z, Šinko G. Enantioseparation, in vitro testing, and structural characterization of triple-binding reactivators of organophosphate-inhibited cholinesterases. Biochem J 2020;477:2771–90. doi: 10.1042/BCJ20200192
- Zandona A, Madunić J, Miš K, Maraković N, Dubois-Geoffroy P, Cavaco M, Mišetić P, Padovan J, Castanho M, Jean L, Renard PY, Pirkmajer S, Neves V, Katalinić M. Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells. Toxicology 2023;494:153588. doi: 10.1016/j.tox.2023.153588
- Zandona A, Jurić M, Jean L, Renard PY, Katalinić M. Assessment of cytotoxic properties of tetrahydroisoquinoline oximes in breast, prostate and glioblastoma cancer cells. Drug Chem Toxicol 2025;48:856–63. doi: 10.1080/01480545.2025.2491534
- Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9
- Eyer P, Worek F, Kiderlen D, Sinko G, Stuglin A, Simeon-Rudolf V, Reiner E. Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal Biochem 2003;312:224–7. doi: 10.1016/S0003-2697(02)00506-7
- Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282–6. doi: 10.1021/jm300871x
- Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141–7. doi: 10.1074/jbc.M210241200
- Zandona A, Maraković N, Mišetić P, Madunić J, Miš K, Padovan J, Pirkmajer S, Katalinić M. Activation of (un)regulated cell death as a new perspective for bispyridinium and imidazolium oximes. Arch Toxicol 2021;95:2737–54. doi: 10.1007/s00204-021-03098-w
- European Collection of Authenticated Cell Cultures (ECACC). Fundamental Ttechniques in Cell Culture: Laboratory Handbook. 4th ed. Darmstadt: Merck KGaA; 2018.
- Dighe SN, Deora GS, De la Mora E, Nachon F, Chan S, Parat MO, Brazzolotto X, Ross BP. Discovery and structure–activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem 2016;59:7683–9. doi: 10.1021/acs.jmedchem.6b00356
- Pajk S, Knez D, Košak U, Zorović M, Brazzolotto X, Coquelle N, Nachon F, Colletier JP, Živin M, Stojan J, Gobec S. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes. J Enzyme Inhib Med Chem 2020;35:498–505. doi: 10.1080/14756366.2019.1710502
- Košak U, Strašek Benedik N, Knez D, Žakelj S, Trontelj J, Pišlar A, Horvat S, Bolje A, Žnidaršič N, Grgurevič N, Švara T, Kljun J, Skrzypczak-Wiercioch A, Lv B, Xiong Y, Wang Q, Bian R, Shao J, Dias J, Nachon F, Brazzolotto X, Stojan J, Sun H, Sałat K, Gobec S. Lead optimization of a butyrylcholinesterase inhibitor for the treatment of Alzheimer’s disease. J Med Chem 2025;68:11693–723. doi: 10.1021/acs.jmedchem.5c00577
- Košak U, Knez D, Ferjančič Benetik S, Mastnak Sokolov P, Pišlar A, Horvat S, Stojan J, Lv B, Zhang W, Wang Y, Wang Q, Igert A, Dias J, Nachon F, Brazzolotto X, Sun H, Gobec S. Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Chem Biol Interact 2025;420:111670. doi: 10.1016/j.cbi.2025.111670
- Košak U, Knez D, Pišlar A, Horvat S, Žakelj S, Igert A, Dias J, Nachon F, Brazzolotto X, Gobec S. N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors. Chem Biol Interact 2025;420:111681. doi: 10.1016/j.cbi.2025.111681
- Pesaresi A. Mixed and non-competitive enzyme inhibition: underlying mechanisms and mechanistic irrelevance of the formal two-site model. J Enzyme Inhib Med Chem 2023;38(1):2245168. doi: 10.1080/14756366.2023.2245168
Language: English, Croatian, Slovenian
Page range: 1 - 8
Submitted on: Nov 1, 2025
Accepted on: Feb 1, 2026
Published on: Mar 30, 2026
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Nikola Maraković, Nicolas Probst, Tena Čadež, Antonio Zandona, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution 4.0 License.